The SYMPLICITY 3-year outcomes are out. Bear in mind this is the largest study we have had so far. It included 535 patients. 364 received renal denervation (RDN) and 171 went to the control group. At 36-month followup, 101 patients crossed over. The procedure was safe at 36 months, both for patients receiving it at…
TCT 2022 | RADIANCE II Pivotal Trial
Renal denervation has been developed to treat blood hypertension. Even though at present is still not common, with the development of new technology and improved technique, its results are promising. The RADIANCE II Pivotal included 224 patients. 150 received renal denervation with ultrasound (uRDN) and 74 went to the control group. Efficacy primary end point…